secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001104659-23-115538
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis reports Q3 2023 net loss of $5.9M; cash $22.1M; NXP800 orphan drug status
--------------------------------------------------------------------------------

- Cash and investments $22.1M at Sep 30, 2023, up from $20.0M at Dec 31, 2022.
- Net loss $5.9M for Q3 2023, unchanged YoY; R&D expenses $4.5M.
- Phase 1b study of NXP800 in platinum-resistant ARID1a-mutated ovarian cancer ongoing; preliminary data expected Q1 2024.
- NXP900 Phase 1a dose escalation initiated in advanced solid tumors; novel preclinical data presented.
- FDA granted NXP800 Orphan Drug Designation for cholangiocarcinoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465923115538/0001104659-23-115538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465923115538/tm2330113d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-115538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer